CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the Australian company’s financial distress since its ill-fated 2022 ...
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...
At the time of writing, the shares are down another 0.22% to $98.33 a piece. Although at one point earlier this morning, the shares were up 2.3% to $100.80 each. It's more bad news for investors after ...
In a 90-day review, CSL told the market it would take another $US5bn ($A6.9bn) non-cash impairment. The first $1.5bn of this was recognised during the first-half ...
GameSpot may receive revenue from affiliate and advertising partnerships for sharing this content and from purchases through links. The Xbox Elite Controller 2 has remained one of the best options for ...
Amid the drama at the biotech, a new figure has stepped up right as the company needs a new long-term chief executive and chairman. Brian McNamee is CSL’s immovable object and unstoppable force. But ...
Shares in health giant CSL tanked today, with the stock closing 16 per cent lower, at $100.75. At earlier points in the session, the stock was down more than 20 per cent, sinking below $100 to decade ...
Biotechnology business CSL, which specialises in bloods, vaccines and plasma products, flagged a US$5 billion (AU$6.9 billion) write-down of its assets. The Melbourne-headquartered company also ...
Investors on Monday stripped billions from CSL’s market capitalisation, triggered by news of the impairment against its unpopular Vifor renal therapy acquisition, and the prospect of revenue and ...
CSL has lost the trust of major investors after slashing earnings forecasts reaffirmed three months ago and announcing one of the biggest write-downs in Australian corporate history as the healthcare ...
Qualcomm has just announced the new Snapdragon 8 Elite Gen 5 SoC, which sports gains across the CPU, GPU, and NPU and supports the APV codec for higher-quality video capture. This new SoC is expected ...
SYDNEY--Pharmaceutical company CSL on Monday downgraded its annual earnings guidance and signaled another $5 billion of pretax impairments, including for the Vifor business that it acquired for $11.7 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results